References
- White T, Özel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 74(4), 293–296 (2006).
- Back DJ, Breckenridge AM, MacIver M et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. Br. J. Clin. Pharmacol. 13(3), 325–330 (1982).
- Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br. J. Obstet. Gynaecol. 104(Suppl. 16), 4–13 (1997).
- Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8(Suppl. 1), 3–63 (2005).
- Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand. 81(6), 482–490 (2002).
- Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 67(1), 93–99 (2003).
- Wiegratz I, Kutschera E, Lee JH et al. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 67(5), 361–366 (2003).
- Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus–pituitary–adrenal axis. Psychosom. Med. 61(2), 154–162 (1999).
- Van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72(3), 168–174 (2005).
- Audet MC, Moreau M, Koltun WD et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. A randomized controlled trial. JAMA 285(18), 2347–2354 (2001).
- Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362(9382), 428–432 (2003).
- Straczek C, Oger E, de Jonage-Canonico MBY et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation 112(22), 3495–3500 (2005).
- Canonico M, Oger E, Conard J et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J. Thromb. Haemost. 4(6), 1259–1265 (2006).
- Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 µg of ethinyl estradiol. Contraception 73(3), 223–228 (2006).
- Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch. Intern. Med. 164(18), 1965–1976 (2004).
- Lopes P, Rozenberg S, de Graaf J, Fernandez-Villoria E, Marianowski L. Aerodiol versus the transdermal route: perspectives for patient preference. Maturitas 38(Suppl. 1), S31–S39 (2001).